US20070148248A1 - Gastric reflux resistant dosage forms - Google Patents

Gastric reflux resistant dosage forms Download PDF

Info

Publication number
US20070148248A1
US20070148248A1 US11/316,830 US31683005A US2007148248A1 US 20070148248 A1 US20070148248 A1 US 20070148248A1 US 31683005 A US31683005 A US 31683005A US 2007148248 A1 US2007148248 A1 US 2007148248A1
Authority
US
United States
Prior art keywords
composition
natural polymer
film
weight
gastric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/316,830
Other languages
English (en)
Inventor
Nachiappan Chidambaram
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Patheon Softgels Inc
Original Assignee
Banner Pharmacaps Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banner Pharmacaps Inc filed Critical Banner Pharmacaps Inc
Priority to US11/316,830 priority Critical patent/US20070148248A1/en
Assigned to BANNER PHARMACAPS, INC. reassignment BANNER PHARMACAPS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHIDAMBARAM, NACHIAPPAN
Priority to ES15163491.2T priority patent/ES2687807T3/es
Priority to JP2008547361A priority patent/JP5627854B2/ja
Priority to ES06845613.6T priority patent/ES2549858T3/es
Priority to CA2633924A priority patent/CA2633924C/en
Priority to EP06845613.6A priority patent/EP1973533B1/en
Priority to PCT/US2006/048029 priority patent/WO2007075475A2/en
Priority to EP14150121.3A priority patent/EP2716283B1/en
Priority to ES14150121.3T priority patent/ES2538803T3/es
Priority to CA2798511A priority patent/CA2798511C/en
Priority to EP15163491.2A priority patent/EP2923696B1/en
Publication of US20070148248A1 publication Critical patent/US20070148248A1/en
Priority to US12/716,593 priority patent/US9693966B2/en
Priority to JP2013119371A priority patent/JP2013209416A/ja
Priority to US14/078,156 priority patent/US8962005B2/en
Priority to US14/507,327 priority patent/US9192582B2/en
Assigned to UBS AG, STAMFORD BRANCH, AS COLLATERAL AGENT reassignment UBS AG, STAMFORD BRANCH, AS COLLATERAL AGENT SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BANNER LIFE SCIENCES LLC
Assigned to BANNER LIFE SCIENCES LLC reassignment BANNER LIFE SCIENCES LLC RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: UBS AG, STAMFORD BRANCH
Assigned to BANNER LIFE SCIENCES LLC reassignment BANNER LIFE SCIENCES LLC NUNC PRO TUNC ASSIGNMENT (SEE DOCUMENT FOR DETAILS). Assignors: BANNER PHARMACAPS INC.
Priority to US15/602,700 priority patent/US10182990B2/en
Assigned to PATHEON SOFTGELS INC reassignment PATHEON SOFTGELS INC NUNC PRO TUNC ASSIGNMENT (SEE DOCUMENT FOR DETAILS). Assignors: BANNER LIFE SCIENCES LLC
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals

Definitions

  • the invention is in the field of gastric resistant dosage forms.
  • enteric dosage forms are well known in the art. Such dosage forms are described in Remington's Pharmaceutical Sciences, 18 th Ed., Mack Publishing Co., Easton, Pa. (1990). Enteric dosage forms are useful for protecting the contents of the dosage form from the gastric conditions of the stomach and/or to protect gastric tissue from an irritant material contained in the dosage form. Enteric dosage forms can also be useful in preventing gastric reflux due to the presence of odor-causing liquids, such as fish oil or garlic oil, in the dosage form.
  • Enteric-coated dosage forms are typically produced by a film coating process, where a thin film layer of an acid-insoluble (enteric) polymer is applied to the surface of a pre-manufactured dosage form, such as a tablet, and to a lesser extent hard and soft capsules.
  • the enteric coating method involves spraying an aqueous or organic solution or suspension of one or more enteric polymers onto tumbling or moving tablets or capsules, followed by drying at elevated temperatures.
  • Enteric dosage forms made by this coating method can suffer from various process-related problems that affect the performance and/or appearance of the coating. For example, “orange peel” surface formation, also known as surface roughness or mottling, may result. More seriously, coat integrity failure may occur, such as cracking or flaking off of the enteric polymer coating. All coating processes present inherent problems, including possible uneven distribution of the coating ingredients, which can occur under multivariate coating processes.
  • WO 2004/03068 by Banner Pharmacaps, Inc. (“the '068 application”) describes a gel mass that is useful in manufacturing enteric soft or hard shell capsules or enteric tablets without the need for a coating.
  • the gel mass comprises a film-forming, water-soluble polymer, an acid-insoluble polymer and optionally, one or more excipients such as plasticizers, colorants and flavorants.
  • the '068 application discloses the use of synthetic acid-insoluble polymers such as cellulosic polymers and acrylic acid-methacrylic acid copolymers (Eudragit®) which are present in a concentration from 8 to 20% by weight of the wet gel mass.
  • U.S. Patent Application Publication No. 2003/0175335 by Scott et al (“the '335 application”) describes film forming compositions containing pectin, at least one film-forming polymer, and a setting system for preparing soft and hard shell capsules.
  • the concentration of pectin is 5 to 60% by weight, preferably 10 to 40% by weight.
  • the concentration of the film-forming polymer is 40 to 95% by weight, preferably 50 to 85% by weight.
  • the '335 application discloses a film containing 5 to 25%, preferably 10 to 20% by weight pectin which is suitable to prepare hard shell capsules with enteric properties.
  • a gastric resistant film-forming composition comprising a gastric resistant film-forming composition which comprises a gastric resistant natural polymer at relatively low concentrations and methods of manufacturing thereof.
  • Gastric resistant film-forming compositions comprise a gastric resistant natural polymer, a film-forming natural polymer, and optionally a gelling agent.
  • the composition can be used for drug delivery either as a liquid or as a gelled capsule.
  • Suitable gastric resistant natural polymers include polysaccharides such as pectin and pectin-like polymers.
  • the concentration of the gastric resistant natural polymer is less than about 5% by weight of the composition, preferably from about 2 to about 4% by weight of the composition.
  • Suitable film-forming natural polymers include gelatin and gelatin-like polymers.
  • the concentration of the film-forming natural polymer is from about 20 to about 40% by weight of the composition, preferably from about 25 to about 40% by weight of the composition.
  • Suitable gelling agents include divalent cations such as Ca 2+ and Mg 2+ .
  • the concentration of the optional gelling agents is less than about 2% by weight of the composition, preferably less than about 1% by weight of the composition.
  • the composition can further comprise one or more plasticizers to facilitate the film-forming process.
  • the film-forming composition can be used to prepare soft or hard shell gelatin capsules which can encapsulate a liquid or semi-solid fill material or a solid tablet (Softlet®) comprising an active agent and one or more pharmaceutically acceptable excipients.
  • the composition can be administered as a liquid with an active agent dissolved or dispersed in the composition.
  • the compositions are not only gastric resistant but may also prevent gastric reflux associated with odor causing liquids, such as fish oil or garlic oil, encapsulated in a unit dosage form as well as esophageal irritation due to the reflux of irritant drugs delivered orally.
  • Gastric resistant natural polymer refers to refers to natural polymers or mixtures of natural polymers which are insoluble in the acidic pH of the stomach.
  • “Film-forming natural polymer” as used here refers to polymers useful for surface coatings that are applied by spraying, brushing, or various industrial processes, which undergo film formation. In most film-formation processes, a liquid coating of relatively low viscosity is applied to a solid substrate and is cured to a solid, high-molecular-weight, polymer-based adherent film possessing the properties desired by the user. For most common applications, this film has a thickness ranging from 0.5 to 500 micrometers (0.0005 to 0.5 millimeters, or 0.00002 to 0.02 inches).
  • “Gelling agent” as used herein refers to substances that undergo a high degree of cross-linking or association when hydrated and dispersed in the dispersing medium, or when dissolved in the dispersing medium. This cross-linking or association of the dispersed phase alters the viscosity of the dispersing medium. The movement of the dispersing medium is restricted by the dispersed phase, and the viscosity is increased.
  • Gastric resistant film-forming compositions comprising (1) a gastric resistant natural polymer; (2) a film-forming natural polymer; and optionally (3) a gelling agent, are described herein.
  • Exemplary gastric resistant natural polymers include pectin and pectin-like polymers which typically consist mainly of galacturonic acid and galacturonic acid methyl ester units forming linear polysaccharide chains.
  • these polysaccharides are rich in galacturonic acid, rhamnose, arabinose and galactose, for example the polygalacturonans, rhamnogalacturonans and some arabinans, galactans and arabinogalactans. These are normally classified according to the degree of esterification.
  • HM high (methyl) ester
  • a relatively high portion of the carboxyl groups occur as methyl esters, and the remaining carboxylic acid groups in the form of the free acid or as its ammonium, potassium, calcium or sodium salts; useful properties may vary with the degree of esterification and with the degree of polymerization.
  • Pectin in which less than 50% of the carboxyl acid units occur as the methyl ester is normally referred to as low (methyl) ester or LM-pectin.
  • low ester pectin is obtained from high ester pectin by a treatment at mild acidic or alkaline conditions.
  • Amidated pectin is obtained from high ester pectin when ammonia is used in the alkaline deesterification process. In this type of pectin some of the remaining carboxylic acid groups have been transformed into the acid amide.
  • the useful properties of amidated pectin may vary with the proportion of ester and amide units and with the degree of polymerization.
  • the gastric resistant natural polymer is pectin.
  • the gastric resistant natural polymer is present in an amount less than about 5% by weight of the composition, preferably from about 2 to about 4% by weight of the composition.
  • Exemplary film-forming natural polymers include gelatin and gelatin-like polymers.
  • the film-forming natural polymer is gelatin.
  • a number of other gelatin-like polymers are available commercially.
  • the film-forming natural polymer is present in an amount from about 20 to about 40% by weigh of the composition, preferably from about 25 to about 40% by weight of the composition.
  • the composition can optionally contain a gelling agent.
  • exemplary gelling agents include divalent cations such as Ca 2+ and Mg 2+ .
  • Source of these ions include inorganic calcium and magnesium salts and calcium gelatin.
  • the gelling agent is present in an amount less than about 2% by weight of the composition, preferably less than about 1% by weight of the composition.
  • plasticizers can be added to the composition to facilitate the film-forming process.
  • Suitable plasticizers include glycerin, sorbitol, sorbitans, maltitol, glycerol, polyethylene glycol, polyalcohols with 3 to 6 carbon atoms, citric acid, citric acid esters, triethyl citrate and combinations thereof.
  • the concentration of the one or more plasticizers is from about 8% to about 30% by weight of the composition.
  • the plasticizer is glycerin and/or sorbitol.
  • the film-forming composition can be used to prepare soft or hard shell gelatin capsules which can encapsulate a liquid or semi-solid fill material or a solid tablet (Softlet®) comprising an active agent and one or more pharmaceutically acceptable excipients.
  • the composition can be administered as a liquid with an active agent dissolved or dispersed in the composition.
  • the film-forming composition can be used to prepare soft or hard capsules using techniques well known in the art.
  • soft capsules are typically produced using a rotary die encapsulation process.
  • Fill formulations are fed into the encapsulation machine by gravity.
  • the capsule shell can comprise one or more plasticizers selected from the group consisting of glycerin, sorbitol, sorbitans, maltitol, glycerol, polyethylene glycol, polyalcohols with 3 to 6 carbon atoms, citric acid, citric acid esters, triethyl citrate and combinations thereof.
  • plasticizers selected from the group consisting of glycerin, sorbitol, sorbitans, maltitol, glycerol, polyethylene glycol, polyalcohols with 3 to 6 carbon atoms, citric acid, citric acid esters, triethyl citrate and combinations thereof.
  • the capsule shell can include other suitable shell additives such as opacifiers, colorants, humectants, preservatives, flavorings, and buffering salts and acids.
  • suitable shell additives such as opacifiers, colorants, humectants, preservatives, flavorings, and buffering salts and acids.
  • Opacifiers are used to opacify the capsule shell when the encapsulated active agents are light sensitive. Suitable opacifiers include titanium dioxide, zinc oxide, calcium carbonate and combinations thereof.
  • Colorants can be used to for marketing and product identification/differentiation purposes. Suitable colorants include synthetic and natural dyes and combinations thereof.
  • Humectants can be used to suppress the water activity of the softgel. Suitable humectants include glycerin and sorbitol, which are often components of the plasticizer composition. Due to the low water activity of dried, properly stored softgels, the greatest risk from microorganisms comes from molds and yeasts. For this reason, preservatives can be incorporated into the capsule shell. Suitable preservatives include alkyl esters of p-hydroxy benzoic acid such as methyl, ethyl, propyl, butyl and heptyl (collectively known as “parabens”) or combinations thereof.
  • parabens alkyl esters of p-hydroxy benzoic acid
  • Flavorings can be used to mask unpleasant odors and tastes of fill formulations. Suitable flavorings include synthetic and natural flavorings; The use of flavorings can be problematic due to the presence of aldehydes which can cross-link gelatin. As a result, buffering salts and acids can be used in conjunction with flavorings that contain aldehydes in order to inhibit cross-linking of the gelatin.
  • Soft capsules can used to deliver a wide variety of pharmaceutically active agents.
  • Suitable agents include analgesics, anti-inflammatory agents, antihelmintics, anti-arrhythmic agents, anti-bacterial agents, anti-viral agents, anti-hypertensive agents, anti-coagulants, anti-depressants, anti-diabetics, anti-epileptics, anti-fungal agents, anti-gout agents, anti-malarials, anti-migraine agents, anti -muscarinic agents, anti-neoplastic agents, erectile dysfunction improvement agents, immunosupressants, anti-protozoal agents, anti-thyroid agents, anxiolytic agents, sedatives, hypnotics, neuroleptics, -blockers, cardiac inotropic agents, corticosteroids, diuretics, anti-parkinsonian agents, gastro-intestinal agents, histamine H 1 and H 2 receptor antagonists, keratolytics, lipid regulating agents, anti-anginal agents, nutritional
  • Fill formulations may be prepared using a pharmaceutically acceptable carrier composed of materials that are considered safe and effective and may be administered to an individual without causing undesirable biological side effects or unwanted interactions.
  • the carrier is all components present in the pharmaceutical formulation other than the active ingredient or ingredients.
  • carrier includes, but is not limited to surfactants, humectants, plasticizers, crystallization inhibitors, wetting agents, bulk filling agents, solubilizers, bioavailability enhancers, pH adjusting agents, and combinations thereof.
  • the composition can be administered as a liquid with an active agent dissolved (e.g. solution) or dispersed (e.g. suspension) in the composition.
  • active agents are described above.
  • the solution or suspension may be prepared using one or more pharmaceutically acceptable excipients. Suitable excipients include, but are not limited to, surfactants, humectants, plasticizers, crystallization inhibitors, wetting agents, bulk filling agents, solubilizers, bioavailability enhancers, pH adjusting agents, flavorants and combinations thereof.
  • composition of the gastric resistant dosage form is shown below.
  • Component % by weight of the Composition Pectin 4.04 Water 70.78 Calcium chloride (CaCl 2 ) 0.05 Gelatin (150 bloom bovine bone) 17.70 Glycerin 7.43
  • composition of the gastric resistant dosage form is shown below. Component % by weight of the composition Pectin 4.04 Water 70.78 Calcium chloride (CaCl 2 ) 0.05 Gelatin (175 bloom pig skin) 17.70 Glycerin 7.43
  • composition of the gastric resistant dosage form is shown below. Component % by weight of the composition Pectin 4.04 Water 70.71 Calcium chloride (CaCl 2 ) 0.05 Gelatin (150 bloom bovine bone) 17.73 Glycerin 7.43
  • composition of the gastric dosage form is shown below. Component % by weight of the composition Pectin 4.04 Water 70.71 Calcium chloride (CaCl 2 ) 0.03 Gelatin (150 bloom bovine bone) 17.75 Glycerin 7.43
  • composition of the gastric dosage form is shown below. Component % by weight of the composition Pectin 4.04 Water 70.71 Calcium chloride (CaCl 2 ) 0.01 Gelatin (150 bloom bovine bone) 17.77 Glycerin 7.43
  • composition of the gastric dosage form is shown below. Component % by weight of the composition Pectin 4.04 Water 70.71 Calcium chloride (CaCl 2 ) 0.007 Gelatin (150 bloom bovine bone) 17.77 Glycerin 7.43
  • composition of the gastric dosage form is shown below. Component % by weight of the composition Pectin 4.04 Water 68.99 Calcium chloride (CaCl 2 ) 0.013 Gelatin (150 bloom bovine bone) 17.79 Glycerin 9.17
  • composition of the gastric dosage form is shown below. Component % by weight of the composition Pectin 4.04 Water 61.89 Calcium chloride (CaCl 2 ) 0.013 Gelatin (150 bloom bovine bone) 22.79 Glycerin 11.27
  • composition of the gastric dosage form is shown below. Component % by weight of the composition Pectin 4.04 Water 54.79 Calcium chloride (CaCl 2 ) 0.013 Gelatin (150 bloom bovine bone) 27.79 Glycerin 13.37
  • composition of the gastric dosage form is shown below. Component % by weight of the composition Pectin 4.04 Water 47.69 Calcium chloride (CaCl 2 ) 0.013 Gelatin (150 bloom bovine bone) 32.79 Glycerin 15.47
  • composition of the gastric dosage form is shown below. Component % by weight of the composition Pectin 2.42 Water 49.11 Calcium chloride (CaCl 2 ) 0.004 Gelatin (150 bloom bovine bone) 33.41 Glycerin 15.05
  • composition of the gastric dosage form is shown below. Component % by weight of the composition Pectin 2.42 Water 49.02 Calcium chloride (CaCl 2 ) 0.008 Gelatin (150 bloom bovine bone) 33.60 Glycerin 15.05
  • composition of the gastric dosage form is shown below. Component % by weight of the composition Pectin 2.42 Water 49.11 Calcium chloride (CaCl 2 ) 0.016 Gelatin (150 bloom bovine bone) 33.41 Glycerin 15.05
  • composition of the gastric dosage form is shown below. Component % by weight of the composition Pectin 2.42 Water 49.11 Calcium chloride (CaCl 2 ) 0.031 Gelatin (150 bloom bovine bone) 33.39 Glycerin 15.05
  • composition of the gastric dosage form is shown below. Component % by weight of the composition Pectin 2.50 Water 47.69 Calcium chloride (CaCl 2 ) 0.0054 Gelatin (150 bloom bovine bone) 34.33 Glycerin 15.47
  • composition of the gastric dosage form is shown below.
  • Component % by weight of the composition Pectin 3.03 Water 49.11 Calcium chloride (CaCl 2 ) 0.0049 Gelatin (150 bloom bovine bone) 32.81 Glycerin 15.05
  • composition of the gastric dosage form is shown below. Component % by weight of the composition Pectin 3.03 Water 47.68 Calcium chloride (CaCl 2 ) 0.0065 Gelatin (150 bloom bovine bone) 33.81 Glycerin 15.47
  • composition of the gastric dosage form is shown below.
  • Component % by weight of the composition Pectin 3.03 Water 49.11 Gelatin (150 bloom bovine bone) 32.81 Glycerin 15.05
  • Typical fill materials include, but are not limited to, fish oil, garlic oil, soybean oil, and medium chain triglycerides (“MCT”).
  • MCT medium chain triglycerides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US11/316,830 2005-12-22 2005-12-22 Gastric reflux resistant dosage forms Abandoned US20070148248A1 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
US11/316,830 US20070148248A1 (en) 2005-12-22 2005-12-22 Gastric reflux resistant dosage forms
EP15163491.2A EP2923696B1 (en) 2005-12-22 2006-12-18 Gastric reflux resistant dosage forms
CA2798511A CA2798511C (en) 2005-12-22 2006-12-18 Gastric reflux resistant dosage forms
JP2008547361A JP5627854B2 (ja) 2005-12-22 2006-12-18 胃の逆流抵抗性投薬形態
ES06845613.6T ES2549858T3 (es) 2005-12-22 2006-12-18 Formas de dosificación resistentes al reflujo gástrico
ES15163491.2T ES2687807T3 (es) 2005-12-22 2006-12-18 Formas de dosificación resistentes al reflujo gástrico
CA2633924A CA2633924C (en) 2005-12-22 2006-12-18 Gastric reflux resistant dosage forms
EP06845613.6A EP1973533B1 (en) 2005-12-22 2006-12-18 Gastric reflux resistant dosage forms
PCT/US2006/048029 WO2007075475A2 (en) 2005-12-22 2006-12-18 Gastric reflux resistant dosage forms
EP14150121.3A EP2716283B1 (en) 2005-12-22 2006-12-18 Gastric reflux resistant dosage forms
ES14150121.3T ES2538803T3 (es) 2005-12-22 2006-12-18 Formas de dosificación resistentes al reflujo gástrico
US12/716,593 US9693966B2 (en) 2005-12-22 2010-03-03 Gastric reflux resistant dosage forms
JP2013119371A JP2013209416A (ja) 2005-12-22 2013-06-06 胃の逆流抵抗性投薬形態
US14/078,156 US8962005B2 (en) 2005-12-22 2013-11-12 Gastric reflux resistant dosage forms
US14/507,327 US9192582B2 (en) 2005-12-22 2014-10-06 Gastric reflux resistant dosage forms
US15/602,700 US10182990B2 (en) 2005-12-22 2017-05-23 Gastric reflux resistant dosage forms

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/316,830 US20070148248A1 (en) 2005-12-22 2005-12-22 Gastric reflux resistant dosage forms

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/716,593 Division US9693966B2 (en) 2005-12-22 2010-03-03 Gastric reflux resistant dosage forms

Publications (1)

Publication Number Publication Date
US20070148248A1 true US20070148248A1 (en) 2007-06-28

Family

ID=38007176

Family Applications (5)

Application Number Title Priority Date Filing Date
US11/316,830 Abandoned US20070148248A1 (en) 2005-12-22 2005-12-22 Gastric reflux resistant dosage forms
US12/716,593 Active 2030-12-26 US9693966B2 (en) 2005-12-22 2010-03-03 Gastric reflux resistant dosage forms
US14/078,156 Expired - Lifetime US8962005B2 (en) 2005-12-22 2013-11-12 Gastric reflux resistant dosage forms
US14/507,327 Expired - Lifetime US9192582B2 (en) 2005-12-22 2014-10-06 Gastric reflux resistant dosage forms
US15/602,700 Expired - Lifetime US10182990B2 (en) 2005-12-22 2017-05-23 Gastric reflux resistant dosage forms

Family Applications After (4)

Application Number Title Priority Date Filing Date
US12/716,593 Active 2030-12-26 US9693966B2 (en) 2005-12-22 2010-03-03 Gastric reflux resistant dosage forms
US14/078,156 Expired - Lifetime US8962005B2 (en) 2005-12-22 2013-11-12 Gastric reflux resistant dosage forms
US14/507,327 Expired - Lifetime US9192582B2 (en) 2005-12-22 2014-10-06 Gastric reflux resistant dosage forms
US15/602,700 Expired - Lifetime US10182990B2 (en) 2005-12-22 2017-05-23 Gastric reflux resistant dosage forms

Country Status (6)

Country Link
US (5) US20070148248A1 (enExample)
EP (3) EP2716283B1 (enExample)
JP (2) JP5627854B2 (enExample)
CA (2) CA2633924C (enExample)
ES (3) ES2538803T3 (enExample)
WO (1) WO2007075475A2 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050031691A1 (en) * 2002-09-11 2005-02-10 Elan Pharma International Ltd. Gel stabilized nanoparticulate active agent compositions
US20130280323A1 (en) * 2012-04-13 2013-10-24 Banner Pharmacaps, Inc. Soft Elastic Capsules Containing Tablets and Liquid or Semisolid Fills and Methods for Their Manufacture
WO2014136038A1 (en) * 2013-03-07 2014-09-12 Capsugel Belgium Nv Hard capsule formulation
WO2015200149A1 (en) * 2014-06-23 2015-12-30 Banner Life Sciences Llc All natural enteric soft capsules comprising active ingredients
WO2023036581A1 (en) * 2021-09-13 2023-03-16 Nutrition & Biosciences Usa 1, Llc A film-forming composition comprising pectin

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
KR101245604B1 (ko) 2007-11-13 2013-03-21 메리테이지 파마, 인크. 코르티코스테로이드 조성물
US20090143343A1 (en) 2007-11-13 2009-06-04 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
WO2013093630A2 (en) 2011-12-22 2013-06-27 Pronova Biopharma Norge As Gelatin/alginate delayed release capsules comprising omega-3 fatty acids, and methods and uses thereof
AU2014240170B2 (en) * 2013-03-15 2018-05-17 Patheon Softgels Inc. Silk-based capsules
CA2911643C (en) 2013-05-23 2018-01-16 Barlean's Organic Oils, Llc Rotary die system
MX2016004487A (es) 2013-10-30 2016-11-10 Banner Life Sciences Llc Capsulas blandas de capa entérica que constan de ácidos grasos poli insaturados.
US9895333B2 (en) 2014-06-26 2018-02-20 Patheon Softgels Inc. Enhanced bioavailability of polyunsaturated fatty acids
HUE053962T2 (hu) 2014-09-11 2021-08-30 Gelita Ag Zselatin/pektin részecskék
WO2016056230A1 (ja) * 2014-10-06 2016-04-14 富士カプセル株式会社 腸溶性ソフトカプセルの製造方法
SG11201702752RA (en) 2014-10-06 2017-06-29 Fuji Capsule Co Ltd Method of Manufacturing Enteric Seamless Soft Capsule
KR20170076675A (ko) 2014-10-31 2017-07-04 발린스 오르개닉 오일스, 엘.엘.씨. 소프트젤을 제조하기 위한 방법 및 장치
ITUB20156821A1 (it) * 2015-12-09 2017-06-09 Altergon Sa CAPSULE DI GELATINA MOLLE A RILASCIO pH INDIPENDENTE
CN105534945B (zh) * 2015-12-29 2020-12-25 仙乐健康科技股份有限公司 一种植物型肠溶软胶囊
DE102022104553A1 (de) * 2022-02-25 2023-08-31 Gelita Ag Magensaftresistente Kapsel und deren Verwendung

Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518433A (en) * 1982-11-08 1985-05-21 Fmc Corporation Enteric coating for pharmaceutical dosage forms
US4816259A (en) * 1987-02-12 1989-03-28 Chase Chemical Company, L.P. Process for coating gelatin capsules
US5146730A (en) * 1989-09-20 1992-09-15 Banner Gelatin Products Corp. Film-enrobed unitary-core medicament and the like
US5164184A (en) * 1990-10-11 1992-11-17 Kim Young S Process for the preparation of pharmaceutical liquid composition containing Bezoar bovis
US5264223A (en) * 1990-03-29 1993-11-23 Japan Elanco Company, Ltd. Hard capsule for pharmaceutical drugs and method for producing the same
US5330759A (en) * 1992-08-26 1994-07-19 Sterling Winthrop Inc. Enteric coated soft capsules and method of preparation thereof
US5431917A (en) * 1992-10-08 1995-07-11 Japan Elanco Company, Ltd. Hard capsule for pharmaceutical drugs and method for producing the same
US5484598A (en) * 1992-08-18 1996-01-16 R.P. Scherer Corporation Soft gelatin medicament capsules with gripping construction
US5540912A (en) * 1992-03-30 1996-07-30 Alza Corporation Viscous suspensions of controlled-release drug particles
US5659003A (en) * 1994-12-21 1997-08-19 Basf Corporation Polyurethane polymer or oligomer having carbamate groups, method for its preparation, and coating composition
US20010024678A1 (en) * 1997-12-26 2001-09-27 Robert Scott Gelatin compositions
US20010036473A1 (en) * 1998-09-28 2001-11-01 Scott Robert A. Enteric and colonic delivery using HPMC capsules
US6482516B1 (en) * 1993-07-20 2002-11-19 Banner Pharmacaps, Inc. Enrobed tablet
US20030166508A1 (en) * 2000-06-07 2003-09-04 Junshou Zhang Biologically active oral preparation that can be site-specific released in colon
US20030175335A1 (en) * 2000-09-01 2003-09-18 Scott Robert Anthony Pectin film compositions
US20030211146A1 (en) * 1998-09-30 2003-11-13 Scott Robert A. Modified starch film compositions
US20040143039A1 (en) * 2002-12-06 2004-07-22 Martha Hollomon Cationic or amphoteric copolymers prepared in an inverse emulsion matrix and their use in preparing cellulosic fiber compositions
US20040224020A1 (en) * 2002-12-18 2004-11-11 Schoenhard Grant L. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
US20040265384A1 (en) * 2000-09-05 2004-12-30 Scott Robert Anthony Composition for soluble films with a new hydrolyzed polysaccharide

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58172313A (ja) 1982-04-01 1983-10-11 Morishita Jintan Kk 腸溶性軟カプセル
JPS58194810A (ja) * 1982-05-07 1983-11-12 Morishita Jintan Kk コ−テイング軟ミニカプセル
US4719112A (en) * 1982-10-29 1988-01-12 Warner-Lambert Company Foam capsules
JPH0427352A (ja) * 1990-05-22 1992-01-30 Fuji Capsule Kk 健康食品用腸溶性軟カプセル
DE4018247A1 (de) * 1990-06-07 1991-12-12 Lohmann Therapie Syst Lts Herstellungsverfahren fuer schnellzerfallende folienfoermige darreichungsformen
JPH05245366A (ja) * 1992-03-04 1993-09-24 Morishita Jintan Kk 内側面が非水溶化された皮膜を有するシームレスカプセルとその製造方法
US20010003647A1 (en) 1995-06-07 2001-06-14 Ji Sun Coreatant-including electrochemiluminescent compounds, methods, systems and kits utilizing same
KR100219918B1 (ko) 1997-07-03 1999-09-01 김윤 대장선택적 약물전달용 조성물
EP1072633A1 (en) 1999-07-22 2001-01-31 Warner-Lambert Company Pullulan film compositions
US6346231B1 (en) * 1999-10-06 2002-02-12 Joar Opheim Flavored gelatin capsule and method of manufacture
KR100379674B1 (ko) * 2000-03-06 2003-04-10 주식회사 서흥캅셀 펙틴과 글리세린의 배합용액을 이용한 셀룰로오스 캅셀 및그의 제조방법
US6620571B2 (en) * 2000-03-17 2003-09-16 Eastman Kodak Company Method for producing microcapsules having improved wall characteristics
US6683019B2 (en) * 2001-06-13 2004-01-27 Abb Lummus Global Inc. Catalyst for the metathesis of olefin(s)
JP4184278B2 (ja) 2001-11-22 2008-11-19 森下仁丹株式会社 非ゼラチン系カプセル皮膜組成物及びそれを用いたカプセル
NO20021592D0 (no) * 2002-04-04 2002-04-04 Fmc Biopolymer As Polysakkaridkapsler og fremgangsmåte ved fremstilling derav
US20040010069A1 (en) 2002-06-27 2004-01-15 Uniroyal Chemical Company, Inc. Rubber compositions and methods for improving the mooney scorch value and cure rate
DK1545475T3 (da) * 2002-10-01 2014-07-28 Banner Pharmacaps Inc Enterisk sammensætning til fremstillingen af blød kapselvæg
ATE340566T1 (de) 2002-12-05 2006-10-15 Symrise Gmbh & Co Kg Nahtlose gefüllte kapseln
KR100505530B1 (ko) * 2003-09-29 2005-08-03 주식회사 서흥캅셀 어류 젤라틴을 이용한 하드 캅셀 및 그의 제조방법
JP4027352B2 (ja) 2004-09-17 2007-12-26 アンリツ株式会社 光ファイバプローブ装置
DE102007039772A1 (de) 2007-08-22 2009-02-26 Cavis Microcaps Gmbh Mikrokapsel und Verfahren zu deren Herstellung
JP5245366B2 (ja) 2007-11-14 2013-07-24 王子ホールディングス株式会社 偏光板およびその製造方法

Patent Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518433A (en) * 1982-11-08 1985-05-21 Fmc Corporation Enteric coating for pharmaceutical dosage forms
US4816259A (en) * 1987-02-12 1989-03-28 Chase Chemical Company, L.P. Process for coating gelatin capsules
US5146730A (en) * 1989-09-20 1992-09-15 Banner Gelatin Products Corp. Film-enrobed unitary-core medicament and the like
US5459983A (en) * 1989-09-20 1995-10-24 Banner Gelatin Products Corp. Tablet enrobing apparatus
US5264223A (en) * 1990-03-29 1993-11-23 Japan Elanco Company, Ltd. Hard capsule for pharmaceutical drugs and method for producing the same
US5164184A (en) * 1990-10-11 1992-11-17 Kim Young S Process for the preparation of pharmaceutical liquid composition containing Bezoar bovis
US5540912A (en) * 1992-03-30 1996-07-30 Alza Corporation Viscous suspensions of controlled-release drug particles
US5484598A (en) * 1992-08-18 1996-01-16 R.P. Scherer Corporation Soft gelatin medicament capsules with gripping construction
US5330759A (en) * 1992-08-26 1994-07-19 Sterling Winthrop Inc. Enteric coated soft capsules and method of preparation thereof
US5431917A (en) * 1992-10-08 1995-07-11 Japan Elanco Company, Ltd. Hard capsule for pharmaceutical drugs and method for producing the same
US6482516B1 (en) * 1993-07-20 2002-11-19 Banner Pharmacaps, Inc. Enrobed tablet
US5659003A (en) * 1994-12-21 1997-08-19 Basf Corporation Polyurethane polymer or oligomer having carbamate groups, method for its preparation, and coating composition
US20010024678A1 (en) * 1997-12-26 2001-09-27 Robert Scott Gelatin compositions
US20010036473A1 (en) * 1998-09-28 2001-11-01 Scott Robert A. Enteric and colonic delivery using HPMC capsules
US20030211146A1 (en) * 1998-09-30 2003-11-13 Scott Robert A. Modified starch film compositions
US20040105835A1 (en) * 1998-09-30 2004-06-03 Scott Robert A. Modified starch film compositions
US20030166508A1 (en) * 2000-06-07 2003-09-04 Junshou Zhang Biologically active oral preparation that can be site-specific released in colon
US20030175335A1 (en) * 2000-09-01 2003-09-18 Scott Robert Anthony Pectin film compositions
US20040265384A1 (en) * 2000-09-05 2004-12-30 Scott Robert Anthony Composition for soluble films with a new hydrolyzed polysaccharide
US20040143039A1 (en) * 2002-12-06 2004-07-22 Martha Hollomon Cationic or amphoteric copolymers prepared in an inverse emulsion matrix and their use in preparing cellulosic fiber compositions
US20040224020A1 (en) * 2002-12-18 2004-11-11 Schoenhard Grant L. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050031691A1 (en) * 2002-09-11 2005-02-10 Elan Pharma International Ltd. Gel stabilized nanoparticulate active agent compositions
US7713551B2 (en) 2002-09-11 2010-05-11 Elan Pharma International Ltd. Gel stabilized nanoparticulate active agent compositions
US20130280323A1 (en) * 2012-04-13 2013-10-24 Banner Pharmacaps, Inc. Soft Elastic Capsules Containing Tablets and Liquid or Semisolid Fills and Methods for Their Manufacture
WO2014136038A1 (en) * 2013-03-07 2014-09-12 Capsugel Belgium Nv Hard capsule formulation
US10172803B2 (en) 2013-03-07 2019-01-08 Capsugel Belgium Nv Hard capsule formulation
WO2015200149A1 (en) * 2014-06-23 2015-12-30 Banner Life Sciences Llc All natural enteric soft capsules comprising active ingredients
US9782374B2 (en) 2014-06-23 2017-10-10 Patheon Softgels Inc. All-natural enteric soft capsules
US9987240B2 (en) 2014-06-23 2018-06-05 Patheon Softgels, Inc. All-natural enteric soft capsules
US20180271817A1 (en) * 2014-06-23 2018-09-27 Patheon Softgels Inc. All-natural enteric soft capsules
US10357467B2 (en) 2014-06-23 2019-07-23 Patheon Softgels, Inc. All-natural enteric soft capsules
WO2023036581A1 (en) * 2021-09-13 2023-03-16 Nutrition & Biosciences Usa 1, Llc A film-forming composition comprising pectin

Also Published As

Publication number Publication date
ES2549858T3 (es) 2015-11-02
ES2687807T3 (es) 2018-10-29
EP1973533A2 (en) 2008-10-01
US8962005B2 (en) 2015-02-24
CA2633924C (en) 2013-11-19
CA2633924A1 (en) 2007-07-05
EP2716283B1 (en) 2015-04-15
JP2013209416A (ja) 2013-10-10
US20170281555A1 (en) 2017-10-05
US20150024044A1 (en) 2015-01-22
CA2798511C (en) 2015-04-14
EP1973533B1 (en) 2015-07-29
EP2923696B1 (en) 2018-07-11
ES2538803T3 (es) 2015-06-24
EP2716283A1 (en) 2014-04-09
CA2798511A1 (en) 2007-07-05
JP5627854B2 (ja) 2014-11-19
EP2923696A1 (en) 2015-09-30
JP2009521269A (ja) 2009-06-04
WO2007075475A2 (en) 2007-07-05
WO2007075475A3 (en) 2007-12-13
US20140072625A1 (en) 2014-03-13
US9693966B2 (en) 2017-07-04
US20100158958A1 (en) 2010-06-24
US9192582B2 (en) 2015-11-24
US10182990B2 (en) 2019-01-22

Similar Documents

Publication Publication Date Title
US10182990B2 (en) Gastric reflux resistant dosage forms
Gullapalli et al. Gelatin and non-gelatin capsule dosage forms
US9861586B2 (en) Chewable soft capsules
JP6317425B2 (ja) シルク系カプセル剤
US20070082046A1 (en) Enteric valproic acid
US20060088590A1 (en) Non-blooming gelatin and non-gelatin formulations
US8309107B2 (en) Stable solutions of orlistat for pharmaceutical dosage forms
JP7719609B2 (ja) 腸溶性硬質カプセル
US20170281554A1 (en) System for upper intestinal delivery of active ingredients

Legal Events

Date Code Title Description
AS Assignment

Owner name: BANNER PHARMACAPS, INC., NORTH CAROLINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CHIDAMBARAM, NACHIAPPAN;REEL/FRAME:017356/0022

Effective date: 20060117

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: UBS AG, STAMFORD BRANCH, AS COLLATERAL AGENT, CONN

Free format text: SECURITY INTEREST;ASSIGNOR:BANNER LIFE SCIENCES LLC;REEL/FRAME:035133/0328

Effective date: 20150305

AS Assignment

Owner name: BANNER LIFE SCIENCES LLC, NORTH CAROLINA

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:UBS AG, STAMFORD BRANCH;REEL/FRAME:036239/0188

Effective date: 20150731

AS Assignment

Owner name: BANNER LIFE SCIENCES LLC, NORTH CAROLINA

Free format text: NUNC PRO TUNC ASSIGNMENT;ASSIGNOR:BANNER PHARMACAPS INC.;REEL/FRAME:038225/0022

Effective date: 20141121

AS Assignment

Owner name: PATHEON SOFTGELS INC, NORTH CAROLINA

Free format text: NUNC PRO TUNC ASSIGNMENT;ASSIGNOR:BANNER LIFE SCIENCES LLC;REEL/FRAME:043032/0619

Effective date: 20170622